We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+4.21%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$418M
AUM Growth
+$84.2M
Cap. Flow
+$97.8M
Cap. Flow %
23.4%
Top 10 Hldgs %
66.46%
Holding
52
New
11
Increased
13
Reduced
15
Closed
5

Top Buys

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$85.1M
2
GERN icon
Geron
GERN
+$6.69M
3
CBAY
Cymabay Therapeutics
CBAY
+$5.28M
4
KROS icon
Keros Therapeutics
KROS
+$5.03M
5
NTLA icon
Intellia Therapeutics
NTLA
+$4.87M

Top Sells

Rank Stock Value
1
ARQT icon
Arcutis Biotherapeutics
ARQT
+$5.52M
2
TELA icon
TELA Bio
TELA
+$5.04M
3
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$4.21M
4
PHAT icon
Phathom Pharmaceuticals
PHAT
+$3.54M
5
KPTI icon
Karyopharm Therapeutics
KPTI
+$2.95M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHAT icon
51
Phathom Pharmaceuticals
PHAT
$723M
– –
-496,000
Closed -$3.54M
RLAY icon
52
Relay Therapeutics
RLAY
$4.26B
– –
-125,500
Closed -$2.07M
1 2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2023 Portfolio in Review

As of Q2 2023, Opaleye Management held 52 positions worth $418M, up 25% from $334M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Opaleye Management deployed $97.8M of net new capital in Q2 2023, opening 11 new positions and adding to 13 existing holdings. Its largest new stake was ACELYRIN: 4,158,638 shares worth $86.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was TELA Bio, an estimated $5.04M trimmed.

  • Opaleye Management's largest Q2 2023 buy was ACELYRIN: 4,158,638 shares worth $86.9M.
  • Opaleye Management added most to Keros Therapeutics in Q2 2023, an estimated $5.03M increase.
  • Opaleye Management's biggest Q2 2023 reduction was TELA Bio, cutting an estimated $5.04M.
  • Opaleye Management fully exited Arcutis Biotherapeutics in Q2 2023, selling an estimated $5.52M.
  • Opaleye Management's ten largest holdings make up 66% of its $418M portfolio in Q2 2023.
  • Opaleye Management opened 11 new positions and closed 5 in Q2 2023.
  • Opaleye Management's portfolio value rose 25% quarter-over-quarter to $418M.

Based on Opaleye Management's 13F filing for Q2 2023, filed 14 Aug 2023.